PARP (Poly ADP-Ribose Polymerase) Inhibitor Market
The global PARP (Poly ADP-Ribose Polymerase) Inhibitor Market size reached 5,623 USD Million in 2024. Looking forward, MarketsGlob expects the market to reach 10,018 USD Million by 2031, exhibiting a growth rate (CAGR) of 8.6% during 2025-2031.
PARP inhibitors are targeted therapies that block the PARP enzyme, which helps repair damaged DNA in cancer cells. By inhibiting this enzyme, these drugs can prevent cancer cell growth, making them effective in treating ovarian, breast, and other cancers.
Market Highlights
- Increasing prevalence of ovarian and breast cancers worldwide
- Rising adoption of targeted cancer therapies
- Growing clinical research and approvals for new PARP inhibitor drugs
- Expansion of oncology treatment centers and personalized medicine approaches
The PARP Inhibitor Market is expected to grow significantly as healthcare systems focus on precision oncology, improved patient outcomes, and innovative cancer therapies.
PARP (Poly ADP-Ribose Polymerase) Inhibitor Market
Market forecast to grow at a CAGR of 8.6%
Note:The image is for illustrative purposes only
Key Players in the Market
The report includes a detailed analysis of both established and emerging companies in the market. Key players are highlighted based on their product offerings and other relevant factors, with consideration given to their year of market entry.
Major players includes
- AstraZeneca
- Tesaro
- Merck & Co
- Clovis Oncology
- Pfizer
- GSK
- Zai Lab
(Please note that the list of players mentioned here is not final. We encourage you to request a sample report to review the most up-to-date list of all relevant players.)
Segmentation for PARP (Poly ADP-Ribose Polymerase) Inhibitor Market
Products Segment Analysis
- Lynparza
- Zejula
- Rubraca
- Talzenna
- Other
Applications Segment Analysis
- Ovarian Cancer
- Breast Cancer
- Other
(Please note that the segmentation provided in this report is not limited to these categories. We can further break down the data into additional segments as per your specific requirements. We encourage you to request a sample report to explore the detailed scope of our research and customized insights.)
Sales Channel Segment Analysis
- Direct Channel
- Distribution Channel
Market segment by Region/Country including:
- North America (United States, Canada, Mexico)
- Europe (Germany, United Kingdom, France, Italy, Russia, Spain, Benelux, Poland, Austria, Portugal, Rest of Europe)
- Asia-Pacific (China, Japan, Korea, India, Southeast Asia, Australia, Taiwan, Rest of Asia Pacific)
- South America (Brazil, Argentina, Colombia, Chile, Peru, Venezuela, Rest of South America)
- Middle East & Africa (UAE, Saudi Arabia, South Africa, Egypt, Nigeria, Rest of Middle East & Africa)
 Inhibitor Market.png "PARP (Poly ADP-Ribose Polymerase) Inhibitor Share by Product Types & Application")
Report Coverage:
| Base Year of the Analysis | 2025 |
|---|---|
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2032 |
| Types Covered | Lynparza, Zejula, Rubraca, Talzenna, Other |
| Applications Covered | Ovarian Cancer, Breast Cancer, Other |
| Companies Covered |
AstraZeneca, Tesaro, Merck & Co, Clovis Oncology, Pfizer, GSK, Zai Lab (Please note that the list of players mentioned here is not final. We encourage you to request a sample report to review the most up-to-date list of all relevant players.) |
| Sales Channels Covered | Direct Channel, Distribution Channel |
| Regions Covered | North America, Europe, Asia-Pacific, South America, Middle East and Africa |
| Countries Covered | United States, Canada, Mexico, Germany, United Kingdom, France, Italy, Russia, Spain, Benelux, Poland, Austria, Portugal, Rest of Europe, China, Japan, Korea, India, Southeast Asia, Australia, Taiwan, Rest of Asia Pacific, Brazil, Argentina, Colombia, Chile, Peru, Venezuela, Rest of South America, UAE, Saudi Arabia, South Africa, Egypt, Nigeria, Rest of Middle East & Africa |
| Customization Scope | We offer extensive customization options for different segments at the region/country-level, ensuring that specific needs are met. Furthermore, our services extend to additional customization based on your unique requirements. |
| Purchase Options | We have three plans to opt for: Standard Plan (PDF), Advanced Plan (PDF + Excel Data Pack) & Extended Plan (PDF + Excel Data Pack + Periodic Update). For more details, please check details of plan types & features. |
Frequently Asked Questions
Clientele
